source
- Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancerDr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…
- Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular target…